Increase in resistance to new fluoroquinolones from 1998 to 2001 in the Bacteroides fragilis group

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 6, 2002, Pages 1055-1057

  Oteo Iglesias, Jesús ^a   Alós, Juan Ignacio ^a   Gómez Garcés, José Luis ^a  

^a HOSPITAL DE MÓSTOLES   (Spain)

Author keywords

Bacteroides; Fluoroquinolone resistance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; CEFOXITIN; CHLORAMPHENICOL; CLINDAMYCIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CHILD; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FECES ANALYSIS; FEMALE; GEOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE;

ANTI-INFECTIVE AGENTS; BACTEROIDES FRAGILIS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0036924275     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf230     Document Type: Article

References (9)

1. Lorber, B. (1995). Bacteroides, Prevotella, and Fusobacterium species (and other medically important anaerobic gram-negative bacilli). In Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th edn (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds), pp. 2195-204. Churchill Livingston, New York, NY, USA.
2. Oteo, J., Aracil, B., Alós, J. I. & Gómez-Garcés, J. L. (2000). High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates. Journal of Antimicrobial Chemotherapy 45, 691-3.
3. Aldridge, K. E., Ashcraft, D. & Bowman, K. A. (1997). Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Antimicrobial Agents and Chemotherapy 41, 484-7.
4. Aldridge, K. E. & Ashcraft, D. S. (1997). Comparison of in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrobial Agents and Chemotherapy 41, 709-11.
5. Weigelt, J. A. & Faro, S. (1998). Antimicrobial therapy for surgical prophylaxis and for intra-abdominal and gynecologic infections. American Journal of Surgery 176, Suppl. 6A, S1-3.
6. National Committee for Clinical Laboratory Standards. (1997). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Fourth edition: Approved Standard M11-A4. NCCLS, Wayne, PA, USA.
7. Snydman, D. R., McDermott, L., Cuchural, G. J., Hetch, D. W., Iannini, P. B., Harrell, L. J. et al. (1996). Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clinical Infectious Diseases 23, Suppl. 1, S54-65.
8. Betriú, C., Gómez, M., Palau, M. L., Sánchez, A. & Picazo, J. J. (1999) Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrobial Agents and Chemotherapy 43, 2320-2.
9. Aldridge, K. E., Ashcraft, D., Cambre, K., Pierson, C. L., Jenkins, S. G. & Rosenblatt, J. E. (2001). Multicenter study of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrobial Agents and Chemotherapy 45, 1238-43.